Digitalis glycosides may be a safe and tolerable addition to optimal guideline medical therapy to reduce worsening heart failure events in patients with HF with mildly reduced or reduced ejection fraction, researchers reported.
Despite recent data from the DECISION study showing digoxin did not reduce the composite endpoint of HF outcomes and mortality, a meta-analysis presented at Heart Failure 2026 indicated digitalis glycosides may improve outcomes by primarily reducing risk for worsening HF events, with no impact on mortality.
“These results suggest digitalis glycosides may be used as

Kwame Osei, MD, one of the first researchers to document ethnic disparities in diabetes and glucose regulation, recently died at age 75 years.
Osei, a Healio | Endocrine Today Editorial Board Member, founded the Global Diabetes Summit, which convened leaders in diabetes research from all around the world.
“Dr. Kwame Osei’s scientific contributions to the field of endocrinology spanned more than 4 decades of hands-on research, patient care, teaching, mentoring and academic leadership,” Healio | Endocrine Today Editorial Board Member Samuel Dagogo-Jack, MD, DSc, professor of medicine &

Lifestyle intervention remains a core component of obesity management, alongside the emergence of more potent pharmacotherapy.
The FDA approval of obesity drugs including semaglutide (Wegovy/Wegovy pill, Novo Nordisk), tirzepatide (Zepbound, Eli Lilly) and orforglipron (Foundayo, Eli Lilly) led to a surge in their use. However, health care professionals continue to emphasize the importance of other aspects of obesity treatment, like lifestyle intervention.
“The biggest mistake we can make right now in obesity medicine is thinking that prescribing a GLP-1 is the entire treatment plan,” Katherine

Click here to read the Cover Story, “Maintaining weight loss in obesity goes beyond GLP-1s: ‘The hard work is just beginning’.”
Obesity is a chronic disease. This statement is clearly at the heart of the answer to this question.
When you look at the data in the STEP 1 trial extension, semaglutide (Wegovy, Novo Nordisk) works very well. But among patients who stopped it, two-thirds regained most of their weight within a year. Then, when you look at the STEP 4 trial, which randomly assigned participants receiving semaglutide 2.4 mg at 1 year to continue the drug or receive placebo, most of the

There is a version of this story that ends well.
A class of molecules with genuine biological potential, freed from bureaucratic delay, reaches patients who need them, backed by solid science and honest clinical data. That version requires patience, rigor and transparency.
What we have instead is something messier: a multi-billion-dollar market, a gray zone of unregulated suppliers, a regulatory system under political pressure, and real people spending real money on compounds that, for most of them, will produce nothing at all. For some, the cost will be far greater than their credit card

As GLP-1 receptor agonists drive unprecedented weight loss, patients are achieving goal weights but face new aesthetic concerns.
Skin laxity related to the use of GLP-1 receptor agonists is now a primary concern in aesthetic medicine, according to Macrene Alexiades, MD, PhD, FAAD, director and founder of the Dermatology & Laser Center of New York and a Healio Dermatology Peer Perspective Board Member. Before or shortly after initiating GLP-1 therapy, patients should consider consulting with a dermatologist or laser specialist to address any adverse skin effects proactively, Alexiades said.

Click here to read the Cover Story, “Specialists strategize on how to address vision issues in children with Down syndrome.”
Just more than 5,700 American babies are born each year with Down syndrome, and the percent of babies born with Down syndrome is increasing every year as families put off having children to a later age.
In total, there are about 250,000 individuals with Down syndrome in the U.S. today. This number is increasing, as advances in treatment have increased the average life expectancy approximately 10 years over the last decade to almost 60 years vs. 79 years for the average

NEW ORLEANS — Education in nephrology is changing rapidly and will look much different from previous decades, according to a speaker at the National Kidney Foundation Spring Clinical Meetings.
“What we were doing 20 years ago from an education standpoint is no longer viable in today’s environment,” Mihran Naljayan, MD, chief medical officer of clinical transformation, home modalities and pediatrics at DaVita and clinical professor of medicine at LSU School of Medicine, told Healio.
During his presentation, Naljayan discussed how patients, clinicians and trainees can all learn about kidney care

Adults who experience hyperglycemia while hospitalized with acute pancreatitis may be at risk for developing diabetes within a few months, according to findings published in Diabetes Care.
As Healio previously reported, the National Institute of Diabetes and Digestive and Kidney Diseases formed the DREAM study, a prospective study aimed at assessing how acute pancreatitis may impact diabetes risk. The study enrolled 395 adults aged 18 to 75 years without preexisting diabetes hospitalized with acute pancreatitis. Glucose measurements during hospitalization were obtained from medical records.

WASHINGTON — Cervical cancer screening rates are down in recent years, but the rising acceptance of self-collection testing could improve adherence, a presenter here said.
According to the American Cancer Society (ACS), screening rates decreased during the COVID-19 pandemic “and still haven’t rebounded, which unfortunately is a continuation of a declining pattern for the past 20 years.”
But ACS, along with ACOG and other medical societies and federal health agencies, recently updated screening guidance to recommend the option of self-collection for average-risk patients